Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q26738985)
Watch
English
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
4960359
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27493615%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 March 2020
review article
1 reference
stated in
Europe PubMed Central
title
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
4960359
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27493615%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 March 2020
main subject
breast cancer
1 reference
based on heuristic
inferred from title
author
Romualdo Barroso-Sousa
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
4960359
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27493615%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 March 2020
Sara M Tolaney
series ordinal
3
object named as
Sara M Tolaney
1 reference
stated in
Europe PubMed Central
PMC publication ID
4960359
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27493615%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 March 2020
author name string
Geoffrey I Shapiro
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
4960359
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27493615%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 March 2020
language of work or name
English
0 references
publication date
22 June 2016
1 reference
stated in
Europe PubMed Central
PMC publication ID
4960359
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27493615%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 March 2020
published in
Breast Care
1 reference
stated in
Europe PubMed Central
PMC publication ID
4960359
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27493615%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 March 2020
volume
11
1 reference
stated in
Europe PubMed Central
PMC publication ID
4960359
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27493615%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 March 2020
issue
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
4960359
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27493615%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 March 2020
page(s)
167-173
1 reference
stated in
Europe PubMed Central
PMC publication ID
4960359
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27493615%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 March 2020
cites work
Comprehensive molecular portraits of human breast tumours
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
7 April 2017
Hallmarks of Cancer: The Next Generation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
7 April 2017
mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
7 April 2017
The Hallmarks of Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
7 April 2017
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
7 April 2017
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
7 April 2017
The retinoblastoma protein and cell cycle control
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
7 April 2017
Targeting CDK4 and CDK6: From Discovery to Therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
7 April 2017
Cancer cell cycles
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
7 April 2017
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
28 September 2017
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
28 September 2017
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
28 September 2017
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
28 September 2017
Response assessment criteria for brain metastases: proposal from the RANO group.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
28 September 2017
The Role of CDK4/6 Inhibition in Breast Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
28 September 2017
Targeting breast cancer with CDK inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
28 September 2017
The history and future of targeting cyclin-dependent kinases in cancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
28 September 2017
CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
28 September 2017
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
28 September 2017
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
28 November 2018
Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4960359
retrieved
28 November 2018
Identifiers
DOI
10.1159/000447284
1 reference
stated in
Europe PubMed Central
PMC publication ID
4960359
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27493615%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 March 2020
PMC publication ID
4960359
1 reference
stated in
Europe PubMed Central
PMC publication ID
4960359
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27493615%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 March 2020
PubMed publication ID
27493615
1 reference
stated in
Europe PubMed Central
PMC publication ID
4960359
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27493615%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 March 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
